108results about "Sugar derivatives" patented technology

The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

This invention provides methods for massive parallel nucleic acid analysis. A closed complex of nucleic acid template, nucleotide and polymerase can be formed during polymerase reaction, absent divalent metal ion. This is used to trap the nucleotide complementary to the next template nucleotide in the closed complex. Detection of the trapped nucleotide allows determination of the sequence of this next correct nucleotide. In this way, sequential nucleotides of a nucleic acid template can be identified, effectively determining the sequence. This method is applied to sequence multiple templates in parallel, particularly if they are immobilized on a solid support.

The conventional synthesis of nucleic acid polymers from several oligonucleotides comprises several cycles of intermediate product synthesis, purification of the intermediate products and synthesis of a full length product (up to a maximum length of approximately 1000 nucleotides). The novel method shall be carried out in one reaction step and result in nucleic acid polymers of more than 1000 nucleotides.According to the invention, two or more linkable oligonucleotides are provided that in a continuous arrangement and after linkage can form a primary strand, and one or more non-linkable oligonucleotides are provided, each of the non-linkable oligonucleotides comprising two adjoining regions, the first of which is complementary to the 3' end of a linkable oligonucleotide and the second of which is complementary to the 5' end of a further linkable oligonucleotide. The linkable oligonucleotides are hybridized with the complementary regions of the non-linkable oligonucleotides and then linked enzymatically, chemically or photochemically.The method is suited for the de novo synthesis of long nucleic acid chains.

The present disclosure relates to methods for isolating, amplifying, and/or analyzing nucleic acids in the presence of an anion exchange material by performing the isolation, amplification and/or analysis step in the presence of at least one anionic compound.

Methods and compositions for producing siRNAs, e.g., in the form of a d-siRNA composition, from dsRNAs are provided. In the subject methods, a dsRNA is contacted with a composition that includes an activity that cleaves dsRNA into siRNAs, where the composition efficiently cleaves dsRNA into siRNAs. siRNAs produced by the subject methods find use in a variety of applications, particularly in applications where the specific reduction or silencing of a gene is desired. Also provided are kits for use in practicing the subject invention.

Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to tamoxifen treatment. The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with ER+ breast cancer with tamoxifen. Additional methods and compositions are provided for predicting tamoxifen responsiveness in cases of ER+ breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.

The present invention relates to fluorescent dyes in general. The present invention provides a wide range of fluorescent dyes and kits containing the same, which are applicable for labeling a variety of biomolecules, cells and microorganisms. The present invention also provides various methods of using the fluorescent dyes for research and development, forensic identification, environmental studies, diagnosis, prognosis, and/or treatment of disease conditions.

The present invention provides certain cationic lipids containing stigmasterol, ergosterol and cholic acid groups. Compounds of the invention are useful, either alone or in combination with other lipid aggregate-forming components (e.g., DOPE, DOSPA, DOTMA or cholesterol) for formulation into liposomes or other lipid aggregates. Such aggregates are cationic, and able to form stable complexes with anionic macromolecules, such as nucleic acids. The cationic lipids of the invention are useful in methods of transfecting cells, particularly to introduce nucleic acids into cells. The invention also related to kits for the preparation of lipid aggregates and to lipid aggregates and compositions for transfection of cells.

Disclosed is a process for extracting xylose and xylitol from a xylose mother liquor or a xylose digest, which comprises, using xylose hydrolysate or xylose mother liquid as the raw material, removing glucose through saccharomyces cerevisiae fermentation, then imitating moving bed, using water as eluent, completely separating xylose from foreign matter such as arabinose, thus obtaining component containing rich xylose.

The invention discloses a novel andrographolide derivative and analogue as well as a preparation method of the novel andrographolide derivative and analogue and an application to the treatment, the prevention and the relief on human viruses and neoplastic diseases. The invention also relates to a medicine composition of the compound and an application as antivirus and anticancer disease medicine. Through chemical synthesis and preparation, semi-synthesis multi-series andrographolide analogues can be obtained.

The present invention is to obtain novel anti-inflammatory agents having decreased antibacterial activity and increased anti-inflammatory action, and is psedoerythromycin derivatives represented by the following general formula [I],wherein R1 and R2 are same or different and each represents H, alkyl, alkynyl, acyl or sulfonyl, in which these groups may optionally have substituents, and Me indicates methyl.

The invention provides a method of RNA interference, which comprises contacting the cell with a fusion protein-double stranded RNA complex, the complex comprising the double stranded RNA segment containing a double stranded RNA of interest and a fusion protein, the fusion protein comprising (1) a targeting moiety, which will specifically binds to a site on a target cell, and (2) a binding moiety, which will bind to the double stranded RNA, wherein the double stranded RNA segment initiates RNA interference in the cell.

The conjugate compositions and methods are useful to elicit/augment an immune response to a tumor or microbial infection or to reduce the severity of autoimmunity, chronic inflammation, allergy, asthma, periodontal disease, and transplant rejection.

The invention discloses a preparation method of nemadectin. According to the invention, a fermentation broth used for producing nemadectin is directly dried by spraying, such that solid powder is obtained; the solid powder is extracted by using an organic solvent, the extract is filtered, and nemadectin in the extract is absorbed by using macroporous resin; nemadectin absorbed by macroporous resin is then eluted; and the eluent is extracted, concentrated, and dried, such that a nemadectin pure product is obtained. According to the invention, a direct spray-drying method is adopted upon the fermentation broth, and the obtained dried solid fermentation bacterium powder is transportation-tolerant, and is easy to store. With the method provided by the invention, the producing of nemadectin degradation product is reduced, the bacterium powder is easy to extract, and the consumption of the extraction solvent is low. The technology is simple, the cost is low, and the method is easy to operate. With the method, the prepared nemadectin has a high HPLC purity of above 90%.

Described herein are methods of inhibiting M-CSF activity, and, in particular, M-CSF/c-fms dependent cell signaling. In a first embodiment of the invention, one administers to a mammal viral vectors that deliver genes experessing antisense c-fms RNA; in a second embodiment, one induces in vivo production of a high-affinity soluble c-fms protein that competes for non-bound M-CSF; in a third embodiment, one administers a ribozyme-viral vector against c-fms mRNA; and in a fourth embodiment, one administers oligodeoxynucleotides that inhibit expression of c-fms gene product. The methods may be used to treat any disease in which M-CSF activity plays a role, and are particularly effective in treating and preventing atherosclerosis.

Embodiments of the present invention are directed primarily, but not exclusively, to a method for treating and preventing cardiovascular disease by inhibiting receptors to M-CSF. Other embodiments of the present invention include any and all biologic and/or pathobiologic phenomena mediated in whole or in part by M-CSF signaling through its receptor. Pathobiologic phenomena include, but are not limited to, disease entities such as osteoporosis, Alzheimer's disease, diabetes mellitus (Type 1 and/or Type 2), infectious diseases, cancer, and inherited disorders characterized by defects in one or more components in the M-CSF signaling pathway.

The present invention provides methods, compositions, and kits for the treatment of disorders associated with overactivation of FGFR3, such as achondroplasia; bone or cartilage disorders; or vascular smooth muscle disorders, or for the elongation of bone. In some embodiments, the present invention provides polypeptides having a natriuretic peptide fused to an Fc domain of an immunoglobulin. Such polypeptides can be administered to subjects, e.g., subcutaneously, to treat a disorder associated with overactivation of FGFR3, a bone or cartilage disorder, or a vascular smooth muscle disorder, or to elongate bone. The invention also features nucleic acid molecules encoding such polypeptides and the use of the nucleic acid molecules for treating disorders associated with overactivation of FGFR3, bone or cartilage disorders, or vascular smooth muscle disorders, or for elongating bone.

The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat patients with compromised genetic disorders.

The present invention provides compositions and methods for the detection and characterization of mutations associated with cystic fibrosis. More particularly, the present invention provides compositions, methods and kits for using invasive cleavage structure assays (e.g. the INVADER assay) to screen nucleic acid samples, e.g., from patients, for the presence of any one of a collection of mutations in the CFTR gene associated with cystic fibrosis. The present invention also provides compositions, methods and kits for screening sets of CFTR alleles in a single reaction container.

A helicidum analog with high selective suppression to acetylcholinesterase and its application in preparing the medicines for preventing and treating senile dementia are disclosed.

The invention relates to polyurethane foam forming compositions which produce hydrophilicized polyurethane foams, in particular foams which are suitable as wound dressing foams. These compositions comprise (I) a polyurethane dispersion and (II) specific additives including one or more alkylpolyglycoside. The process of producing these foams comprises frothing and drying these polyurethane foam forming compositions.

This invention relates to cellulose II phosphate which may be partly carbamidated, and also to a metal-adsorbing material making use of the same. This cellulose II phosphate efficiently adsorbs metal ions in a solution, and can be used as a metal-adsorbing material and in a metal-adsorbing system.

The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to novel human secreted IGFBP-like polypeptides. Other aspects of the invention include vectors containing processes for producing novel human secreted IGFBP-like polypeptides, compositions, and methods of use for such polypeptides including in cancer.

There are described novel 5-O-mycaminosyltylonide (OMT) analogs possessing increased antibacterial activity toward Gram positive and Gram negative bacteria as well as macrolide resistant Gram positives and pharmaceutically acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier. Also described are a method for treating bacterial infections by administering to a patient a pharmaceutical composition containing a therapeutically-effective amount of a compound of the invention, and processes for the preparation of such compounds

The invention provides for the use of sulfur nucleophiles in analyzing methylated DNA and novel sulfur nucleophiles suitable for such us.

Present invention relates to the Biomarkers for detecting high altitude adaptation and hypoxia responsiveness and the method thereof. The invention specifically relates to the Gene variants SNPIDs rs479200 and rs480902 in the first intron of EGLN1 (Prolyl Hydroxylase 2) gene as biomarkers for adaptation to high altitude and predisposition for high altitude pulmonary edema and hypoxia responsiveness using a novel integrative approach of phenotyping concepts of Ayurveda with population genetics, and disease genomics. More specifically, the C allele of SNP ID rs480902 and T allele of rs479200 of EGLN1 gene is more frequent in patients of HAPE and nearly absent in native highlanders. The present invention also provides primers and methods suitable for the detection of these allelic variants for the prediction of individual's adaptability to high altitude and hypoxia and/or the genetic analysis of the EGLN1 gene in a population.

Methods and devices for isolating nucleic acids from a mixture containing such nucleic acids and extraneous matter are provided. In one embodiment, the method of the invention comprises passing the mixture through a glass frit under conditions effective to separate the nucleic acids from the extraneous matter. In a more specific embodiment, the glass frit is a sintered glass frit.